+
Site Tour

Search

  • Connext

    ConnextTV Visit our dedicated channel  for the latest videos, animations  and interviews.   Find out more Therapies Valvular Diseases …
  • Clinical Data

    The objective of this trial is to evaluate the safety and effectiveness of the Amulet™ LAA Occluder compared to NOAC therapy in patients with non-valvular AF at increased risk for ischemic stroke…
  • Guidelines

    © Abbott 2024. All rights reserved. 9-EH-5-14475-01 12-2024 REV A Summary of current relevant international guidelines on the diagnosis of TR TR should be evaluated first by echocardiography.…
  • Overview

    TRICUSPID REGURGITATION Tricuspid Valve Disease (TVD), including TR and tricuspid stenosis, is estimated to affect >70 million people worldwide.5 In Europe, the rate of moderate or greater TR is…
  • Clinical Data

    SWITCH TO THE REFERRAL VIEW    For more information specific to neurology regarding LAA Occlusion STROKE RISK REDUCTION AND FREEDOM FROM ANTICOAGULANTS Clinical studies have shown…
  • Transcatheter Repair

    There are patients with TR for whom open heart surgery is contraindicated due to their high risk of poor outcomes or mortality. Factors that define a high-risk patient include old age, the presence…
  • Options

    The European Society of Cardiology/European Association of Cardiothoracic Surgery (ESC/EACTS) guidelines 2021 recommend timely referral of patients with VHD before irreversible damage occurs, and…
  • Surgical Repair or Replacement

    Surgery is recommended in symptomatic patients with severe primary TR.39 Surgical intervention should also be considered early in selected patients with secondary TR who are appropriate for…
  • Medical Management

    Treatment options for the medical management of TR are extremely limited,31 and do not address the underlying pathology of TR. There are no specific pharmaceutical options for treating TR itself,…
  • Diagnosis

    Most early-stage TR is clinically silent,1 and even with severe TR, some patients may be asymptomatic.27 In patients who become symptomatic of TR, the prevalence and severity of the symptoms are…

You are about to leave my-connext.com

You are now leaving my-connext.com. Abbott is not responsible for any content published on the third-party website you are about to enter. Abbott has not reviewed and does not endorse any information presented on third-party websites.

The content on this website is intended for healthcare professionals in EMEA with applicable health authority product registrations, excepted those practicing in France as some of the content is not in compliance with the French Advertising law N°2011-2012 dated 29th December 2011 article 34. Click OK to confirm you are a healthcare professional to proceed.

OK Decline